Serum levels of free light chains and syndecan-1 in patients with rheumatoid arthritis and systemic lupus erythematosus
Authors' conclusion
Elevated serum levels of FLCs and SDC-1 in RA and SLE patients compared with HD underscore their potential as biomarkers for SARDs.
Study context
- Population
- Patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) and healthy donors; serum SDC-1 and κ- and λ-FLCs
- Participants
- 60 / 60 / 50
- Exposure
- RA and SLE vs healthy donors
- RAn = 60
- SLEn = 60
- Healthy donors (HD)n = 50reference
- Outcome
- Serum SDC-1, κ-FLC, λ-FLC and κ/λ ratio
Methodological detailsretrospective analysis of sera, Kruskal-Wallis test, Wilcoxon Mann-Whitney U test, multivariable linear regression, Spearman's correlation
- Retrospective analysis of sera
- Kruskal-Wallis test
- Wilcoxon Mann-Whitney U test
- Multivariable linear regression
- Spearman's correlation
Main finding
As reported in the abstract
- SDC-1, κ-FLC and λ-FLC significantly increased in RA and SLE vs HD
- P < 0.001
- No significant differences in κ/λ ratio among the groups
- P = 0.4
Observational data: associations, not effects.
Further findings
- Significant difference in subject age among groups
Original publication
Serum levels of free light chains and syndecan-1 in patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (Oxford). Published 7 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →